Omeros Corporation
OMER
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.4B
$18.61
▼ -3.32%
P/E
9.74
Mkt Cap
$1.4B
52-Wk Range
$3.94–$19.65
52-Week Range
$3.94 - $19.65
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 352.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary MASP-2 and MASP-3 inhibitor platforms with multiple clinical candidates addressing large orphan disease markets
- Diversified pipeline spanning complement, addiction, oncology, and CNS indications reducing single-asset risk
- Advanced clinical stage programs with completed pivotal trials positioning for potential near-term regulatory approvals and commercialization
- Experienced management team and established infrastructure for drug discovery and development in high-value therapeutic areas
Bear Case
1 risk
- High volatility (beta 2.5). Larger-than-normal price swings expected.
Growth
Stable outlook
Emerging player in Biotechnology
Value
Fairly valued vs Biotech & Therapeutics peers
Momentum
Hot
+73.9% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying OMER right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 13, 2026
Reported EPS of $0.15 vs -$0.27 consensus (+155.9% surprise). Revenue of $28.5M vs $12.7M expected (+124.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+155.9%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$33.00
▲ +77.3% vs $18.61
Latest: HC Wainwright · Jul 27, 2026
1 analyst covering
vs Industry
How OMER stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related